Seeking Alpha

Prosensa flies after update on Drisapersen

  • "We are encouraged by these results that suggest that treating earlier in the disease and treating longer shows a delay in the progression of the disease," says Prosensa (RNA +28.6%) CEO Hans Schikan.
  • The analysis of 96-week extension data shows a 49 meter difference between those on continual treatment and those who had been on a placebo for 48 weeks followed by active drug.
  • Press release
  • At the moment, the company is presenting further details of the results at the JPMorgan healthcare conference.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)